Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Therapies with genetically modified T cells that express chimeric antigen receptors (CARs) specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell malignancies. However, translating these successes into treatments for patients with solid tumours presents various challenges, including the risk of clinically serious...
Alternative Titles
Full title
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10278599
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10278599
Other Identifiers
ISSN
1759-4774
E-ISSN
1759-4782
DOI
10.1038/s41571-022-00704-3
